IgG Complement Activation Measurement via C5a Fragment Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating the side effects of intravenous immunoglobulin G (IVIG) are complex and lack sensitivity, particularly in assessing complement activation, which is crucial for selecting high-quality IVIGs with minimal side effects.
Innovation Solution
A method involving the preparation of IVIG samples and native human serum, mixed at specific ratios and temperatures, followed by incubation and measurement of the C5a fragment to assess complement activation, providing a sensitive and predictive test for IVIG quality and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If the AAC test or Coombs test is used to evaluate complement activation, then side effects can be assessed, but the test complexity increases and sensitivity is insufficient
Solution Approach 1:
The invention extracts and measures only the specific C5a fragment produced during complement activation, rather than measuring total complement activity or requiring complex lysis assays. This extraction of the key indicator molecule enables sensitive and specific detection of complement activation by IVIG without the complexity of traditional AAC or Coombs tests
Solution Approach 2:
The invention replaces the mechanical and procedural complexity of the AAC test (which requires guinea pig complement, sheep erythrocytes, rabbit antibodies, and lysis measurements) with a direct immunological assay for C5a fragment. This substitution simplifies the test system while maintaining or improving sensitivity for detecting complement activation
2Measurement precision
If standard IVIG quality control methods are used, then manufacturing processes are validated, but the ability to discriminate between different IVIG qualities is insufficient
Solution Approach 1:
The invention changes the measurement parameter from general complement activity or antibody binding to the specific quantification of C5a fragment concentration. This parameter change enables fine discrimination between different IVIG preparations based on their complement activation potential, allowing selection of products with minimal side effects
3Reliability
If IVIG is administered to treat immune disorders, then therapeutic benefits are achieved, but side effects such as renal failure and hemolytic anemia may occur
Solution Approach 1:
The invention provides a feedback mechanism for IVIG quality control by measuring complement activation potential before administration. This feedback allows selection of IVIG batches with low complement activation, thereby reducing the risk of side effects while maintaining therapeutic efficacy
Solution Approach 2:
The invention performs preliminary assessment of complement activation potential using the C5a fragment measurement method before IVIG administration. This preliminary action identifies and eliminates high-risk batches, preventing side effects before they occur in patients
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the precise discrimination between different IVIG qualities, effectively reducing side effects by measuring complement activation, thereby ensuring better tolerance and safety for patients.
Implementation Method 1
METHOD FOR MEASURING IgG-MEDIATED COMPLEMENT ACTIVATION... measurement of the amount of C5a fragment in the cooled reaction mixture obtained in c)
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to a method for measuring IgG-mediated complement activation, comprising the following steps: a) preparing a sample A of immunoglobulin G and a sample B containing natural serum, said natural serum optionally being diluted in a dilution buffer; b) mixing sample A with sample B at a ratio (amount of IgG in A in grams:volume of natural serum in B in litres) of between 30 and 75, at a temperature of between 2 °C and 6 °C, and subsequently incubating the resulting reaction mixture at a temperature of between 35 °C and 40 °C for a period of between 30 minutes and 2 hours; c) cooling the reaction mixture obtained at the end of step b) to a temperature of between 0 °C and 4 °C in the presence of EDTA; and d) measuring the quantity of C5a fragment in the cooled reaction mixture obtained in c).